Cambridge Research Biochemicals is expanding its antibody offering to include monoclonal antibody production through agreements with Babraham Bioscience Technologies and Epitomics.
CRB and BBT have formed an alliance that will enable CRB to market custom monoclonal antibody projects (via mouse/rat hybridomas) from BBT.
The companies said the alliance will provide customers with a broader based expertise combining CRB capability in peptide synthesis for antigen use and the Mab production skills of BBT.
CRB has also established a relationship with Epitomics that will enable CRB's rabbit polyclonal antibody projects to be transferred to Epitomics' rabbit monoclonal antibody (Rabmabs) projects.
The resulting combined service will enable both commercial and non-commercial organisations to access the unique Rabmabs technology for research, diagnostics and therapeutics.
